Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast

Background: In registration trials, zafirlukast, an asthma medication, caus ed asymptomatic elevated aminotransferase levels in up to 5% of participant s. Until now, however, no cases of severe hepatitis attributed to zafirluka st have been reported. Objective: To report the clinical characteristics of three patients with se vere hepatitis due to zafirlukast. Design: Case report. Setting: One community hospital and two university hospitals. Patients: Three middle-aged women taking zafirlukast, 20 mg twice per day. Intervention: Discontinuation of zafirlukast therapy in three patients, ste roid therapy in two patients, and orthotopic liver transplantation in one p atient. Measurements: Serum aminotransferase and bilirubin levels, standard blood t ests for causes of hepatitis other than drug toxicity, and liver biopsy in two patients. Results: Patient 1 recovered spontaneously, had a severe relapse after inad vertent rechallenge with the medication, and ultimately made a complete rec overy. Patient 2 developed subfulminant hepatic failure and required liver transplantation. Patient 3 developed severe hepatitis that improved after t reatment with corticosteroids. Liver tissue was available from two patients and showed histologic changes commonly associated with drug reactions. Conclusion: Patients receiving zafirlukast may develop severe liver injury and should be observed for signs and symptoms of hepatitis.